ベバシズマブ・バイオシミラーの世界市場レポート 2025年

ベバシズマブ・バイオシミラー市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.1％で22億7,000万米ドルに成長します。予測期間の成長は、がん治療に対する需要の高まり、バイオシミラー開発の専門知識、ヘルスケアシステムの圧力、バイオシミラーの規制状況、バイオシミラーの互換性などに起因すると考えられます。予測期間における主な動向としては、共同研究・提携、規制の進展と承認、バイオシミラー開発とイノベーション、市場参入戦略、バイオシミラーライフサイクルマネジメントなどが挙げられます。

がん罹患率の増加が今後のベバシズマブ・バイオシミラー市場の成長を牽引すると予測されます。がん罹患率とは、特定の期間における定義された集団の新規がん罹患数を指します。ベバシズマブは腫瘍の血管新生を阻害する生物学的製剤であり、腫瘍の縮小や増殖抑制につながる可能性があります。進行した非小細胞肺がんや転移性大腸がんの患者に対する有効性と安全性の点で、参考となる生物学的製剤と同等です。例えば、2024年10月、英国の国民保健サービス（NHS）は、2022年に346,217件の新規がん診断を報告し、これは1日平均948件です。これは2021年の329,664件から5％の増加です。さらに、がんの診断数は7％増加し、2022年には167,917例から180,877例となった。その結果、がん患者の有病率の増加がベバシズマブ・バイオシミラー市場を牽引しています。

ヘルスケア支出の増加は、今後のベバシズマブ・バイオシミラー市場の成長を促進すると予測されています。ヘルスケア支出とは、特定の期間内にヘルスケア商品やサービスに費やされた金額の合計を指し、一般的には金額で表されます。ベバシズマブ・バイオシミラーは、先発医薬品に代わる費用対効果の高い代替品を提供することで、ヘルスケア支出に大きな影響を与える役割を果たします。例えば、2022年、英国の国家統計局であるOffice for National Statisticsは、英国のヘルスケア支出が約2,830億ポンドに達したと報告しました。これは2021年の支出に比べ、名目ベースで0.7％の増加を反映しています。このように、ヘルスケア支出の増加がベバシズマブ・バイオシミラー市場を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ベバシズマブ・バイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のベバシズマブ・バイオシミラー市場：成長率分析
• 世界のベバシズマブ・バイオシミラー市場の実績：規模と成長, 2019-2024
• 世界のベバシズマブ・バイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界ベバシズマブ・バイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のベバシズマブ・バイオシミラー市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アバスチン
• ムヴァシ
• ジラベフ
• アイビンティオ
• その他の製品
• 世界のベバシズマブ・バイオシミラー市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• オンライン薬局
• 小売薬局
• その他の流通チャネル
• 世界のベバシズマブ・バイオシミラー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 大腸がん
• 非小細胞肺がん
• 神経膠芽腫
• 腎細胞がん
• 子宮頸がん
• 卵巣がん
• 世界のベバシズマブ・バイオシミラー市場アバスチンのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オリジナルアバスチン製品
• 世界のベバシズマブ・バイオシミラー市場、Mvasiのサブセグメンテーション、製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• Mvasi（アムジェンバイオシミラー）
• 世界のベバシズマブ・バイオシミラー市場、ジラベフのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ジラベブ（ファイザーバイオシミラー）
• 世界のベバシズマブ・バイオシミラー市場、Aybintioのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アイビンティオ（サムスンバイオエピスバイオシミラー）
• 世界のベバシズマブ・バイオシミラー市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 追加のベバシズマブ・バイオシミラー

第7章 地域別・国別分析

• 世界のベバシズマブ・バイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のベバシズマブ・バイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ベバシズマブ・バイオシミラー市場：競合情勢
• ベバシズマブ・バイオシミラー市場：企業プロファイル
  • Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • Reliance lifesciences Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Fujifilm Kyowa Kirin Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Teva Pharmaceutical Industries Ltd.
• Mylan Inc.
• Daiichi Sankyo Company Limited
• Beaconpharma Ltd.
• Innovent Biologics Inc.
• STADA Arzneimittel AG
• Shanghai Henlius Biotech Inc.
• Aurobindo Pharma Ltd.
• Dr. Reddy's Laboratories Ltd.
• Biocon Ltd.
• Intas Pharmaceuticals Ltd.
• Amneal Pharmaceuticals LLC
• Samsung Bioepis Co. Ltd.
• Celltrion Inc.
• Coherus BioSciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ベバシズマブ・バイオシミラー市場2029：新たな機会を提供する国
• ベバシズマブ・バイオシミラー市場2029：新たな機会を提供するセグメント
• ベバシズマブ・バイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Bevacizumab biosimilars are a specific class of medications that closely resemble a reference biologic drug named bevacizumab. These biosimilars are designed to mimic the original drug's properties and are frequently utilized to impede the formation of new blood vessels within tumors. By inhibiting this process, they effectively decelerate the progression of tumors.

Bevacizumab biosimilar products, including Avastin, Mvasi, Zirabev, Aybintio, and similar alternatives, represent a range of anti-angiogenic therapies designed to impede new blood vessel formation. These products are accessible through diverse distribution channels such as hospital pharmacies, online platforms, and retail outlets. Their applications span across treating colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer.

The bevacizumab biosimilar market research report is one of a series of new reports from The Business Research Company that provides bevacizumab biosimilar market statistics, including bevacizumab biosimilar industry global market size, regional shares, competitors with a bevacizumab biosimilar market share, detailed bevacizumab biosimilar market segments, market trends, and opportunities, and any further data you may need to thrive in the bevacizumab biosimilar industry. This bevacizumab biosimilar market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The bevacizumab biosimilars market size has grown strongly in recent years. It will grow from $1.53 billion in 2024 to $1.66 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to patent expiry, cost containment in healthcare, increasing incidence of cancer, market competitiveness, patient access and affordability, biosimilar acceptance.

The bevacizumab biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.27 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to rising demand for cancer therapies, biosimilar development expertise, healthcare system pressures, biosimilar regulatory landscape, biosimilar interchangeability. Major trends in the forecast period include collaborations and partnerships, regulatory advancements and approvals, biosimilar development and innovation, market access strategies, biosimilar lifecycle management.

The increasing incidence of cancer cases is anticipated to drive the growth of the bevacizumab biosimilars market in the future. Cancer incidence refers to the number of new cancer cases in a defined population over a specific period. Bevacizumab is a biologic that inhibits tumor angiogenesis, potentially leading to tumor shrinkage and growth inhibition. It is comparable to reference biologics in terms of efficacy and safety for treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For example, in October 2024, the UK's National Health Service (NHS) reported 346,217 new cancer diagnoses in 2022, averaging 948 cases per day. This marks a 5% increase from the 329,664 diagnoses in 2021. Additionally, cancer diagnoses saw a 7% rise, going from 167,917 to 180,877 in 2022. Consequently, the growing prevalence of cancer cases is driving the bevacizumab biosimilars market.

The rising healthcare expenditure is projected to drive the growth of the bevacizumab biosimilars market in the future. Healthcare expenditure refers to the total amount of money spent on healthcare goods and services within a specific timeframe, typically expressed as a monetary value. The bevacizumab biosimilars play a significant role in influencing healthcare expenditure by providing cost-effective alternatives to the originator drug. For example, in 2022, the Office for National Statistics, a UK-based national statistical authority, reported that healthcare expenditure in the UK reached approximately £283 billion. This reflects a 0.7% increase in nominal terms compared to spending in 2021. Thus, the rise in healthcare expenditure is driving the bevacizumab biosimilars market.

Product innovation has become a prominent trend gaining traction in the bevacizumab biosimilars market. Key market players are strategically focusing on the development of inventive products to enhance their market positions. An illustrative example is the collaborative effort of Viatris, a US-based pharmaceutical company, and Biocon Biologics, a US-based pharmaceutical company, in May 2022, resulting in the launch of a biosimilar named Abevmy (bevacizumab). This biosimilar is designed to mirror Roche's Avastin (bevacizumab) and has received approval from Health Canada for application in four oncology indications. Abevmy boasts efficacy, safety, and quality comparable to the reference biologic, as it is a synthesized humanized monoclonal antibody (MA) that binds to and neutralizes the biologic action of human vascular endothelial growth factor (VEGF). This exemplifies the trend of product innovation as a strategic focus within the bevacizumab biosimilars market.

Leading companies in the bevacizumab biosimilars market are strategically engaging in collaborations to develop Next-Generation Biosimilars, a move aimed at fortifying and sustaining their market positions. Next-generation biosimilars contribute to the advancement of the bevacizumab biosimilars market through technological enhancements, improved manufacturing processes, and heightened therapeutic efficacy. A noteworthy example is the exclusive partnership formed in May 2022 between Prestige Biopharma, a Singapore-based pharmaceutical company, and Intas Pharmaceuticals, a multinational pharmaceutical company based in India. This collaboration focuses on Prestige's bevacizumab biosimilar, HD204, currently in Phase III development and designed to replicate Roche's Avastin for various cancers. The exclusive agreement covers key regions such as the US, Europe, and parts of Asia and Africa. With HD204 positioned to offer advancements in bevacizumab biosimilar technology, the collaboration allows Intas Pharmaceuticals to commercialize the biosimilar, leveraging its robust sales and marketing capabilities. This strategic alignment supports Prestige's broader goal of expanding market reach and providing affordable access to patients through its innovative bevacizumab production technology.

In November 2022, Biocon Biologics Ltd., an India-based firm and subsidiary of Biocon Ltd. engaged in the manufacturing of biopharmaceuticals, successfully acquired Viatris Inc.'s global biosimilars business for an undisclosed amount. This strategic acquisition is geared towards reinforcing Biocon Biologics' presence in the biosimilars market. Viatris Inc., based in the US, is a pharmaceutical and healthcare company specializing in medicines for major therapeutic areas, including cancer, with notable products such as Bevacizumab.

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy's Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the bevacizumab biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bevacizumab biosimilars market consists of sales of byvasda, cizumab, alymsys, bevax, and cyramza. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bevacizumab Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bevacizumab biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for bevacizumab biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bevacizumab biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Avastin; Mvasi; Zirabev; Aybintio; Other Products
• 2) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy; Other Distribution Channels
• 3) By Application: Colorectal Cancer; Non-small Cell Lung Cancer; Glioblastoma; Renal Cell Carcinoma; Cervical Cancer; Ovarian Cancer
• Subsegments:
• 1) By Avastin: Original Avastin Product
• 2) By Mvasi: Mvasi (Amgen Biosimilar)
• 3) By Zirabev: Zirabev (Pfizer Biosimilar)
• 4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)
• 5) By Other Products: Additional Bevacizumab Biosimilars
• Companies Mentioned: Cipla Limited; Reliance lifesciences Pvt. Ltd.; Fujifilm Kyowa Kirin Biologics Co. Ltd.; Pfizer Inc.; F. Hoffmann-La Roche Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Bevacizumab Biosimilars Market Characteristics

3. Bevacizumab Biosimilars Market Trends And Strategies

4. Bevacizumab Biosimilars Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Bevacizumab Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Bevacizumab Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Bevacizumab Biosimilars Market Growth Rate Analysis
• 5.4. Global Bevacizumab Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Bevacizumab Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Bevacizumab Biosimilars Total Addressable Market (TAM)

6. Bevacizumab Biosimilars Market Segmentation

• 6.1. Global Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Avastin
• Mvasi
• Zirabev
• Aybintio
• Other Products
• 6.2. Global Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Distribution Channels
• 6.3. Global Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colorectal Cancer
• Non-small Cell Lung Cancer
• Glioblastoma
• Renal Cell Carcinoma
• Cervical Cancer
• Ovarian Cancer
• 6.4. Global Bevacizumab Biosimilars Market, Sub-Segmentation Of Avastin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Original Avastin Product
• 6.5. Global Bevacizumab Biosimilars Market, Sub-Segmentation Of Mvasi, By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mvasi (Amgen Biosimilar)
• 6.6. Global Bevacizumab Biosimilars Market, Sub-Segmentation Of Zirabev, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Zirabev (Pfizer Biosimilar)
• 6.7. Global Bevacizumab Biosimilars Market, Sub-Segmentation Of Aybintio, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Aybintio (Samsung Bioepis Biosimilar)
• 6.8. Global Bevacizumab Biosimilars Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Additional Bevacizumab Biosimilars

7. Bevacizumab Biosimilars Market Regional And Country Analysis

• 7.1. Global Bevacizumab Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Bevacizumab Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Bevacizumab Biosimilars Market

• 8.1. Asia-Pacific Bevacizumab Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Bevacizumab Biosimilars Market

• 9.1. China Bevacizumab Biosimilars Market Overview
• 9.2. China Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Bevacizumab Biosimilars Market

• 10.1. India Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Bevacizumab Biosimilars Market

• 11.1. Japan Bevacizumab Biosimilars Market Overview
• 11.2. Japan Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Bevacizumab Biosimilars Market

• 12.1. Australia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Bevacizumab Biosimilars Market

• 13.1. Indonesia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Bevacizumab Biosimilars Market

• 14.1. South Korea Bevacizumab Biosimilars Market Overview
• 14.2. South Korea Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Bevacizumab Biosimilars Market

• 15.1. Western Europe Bevacizumab Biosimilars Market Overview
• 15.2. Western Europe Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Bevacizumab Biosimilars Market

• 16.1. UK Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Bevacizumab Biosimilars Market

• 17.1. Germany Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Bevacizumab Biosimilars Market

• 18.1. France Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Bevacizumab Biosimilars Market

• 19.1. Italy Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Bevacizumab Biosimilars Market

• 20.1. Spain Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Bevacizumab Biosimilars Market

• 21.1. Eastern Europe Bevacizumab Biosimilars Market Overview
• 21.2. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Bevacizumab Biosimilars Market

• 22.1. Russia Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Bevacizumab Biosimilars Market

• 23.1. North America Bevacizumab Biosimilars Market Overview
• 23.2. North America Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Bevacizumab Biosimilars Market

• 24.1. USA Bevacizumab Biosimilars Market Overview
• 24.2. USA Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Bevacizumab Biosimilars Market

• 25.1. Canada Bevacizumab Biosimilars Market Overview
• 25.2. Canada Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Bevacizumab Biosimilars Market

• 26.1. South America Bevacizumab Biosimilars Market Overview
• 26.2. South America Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Bevacizumab Biosimilars Market

• 27.1. Brazil Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Bevacizumab Biosimilars Market

• 28.1. Middle East Bevacizumab Biosimilars Market Overview
• 28.2. Middle East Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Bevacizumab Biosimilars Market

• 29.1. Africa Bevacizumab Biosimilars Market Overview
• 29.2. Africa Bevacizumab Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Bevacizumab Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Bevacizumab Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Bevacizumab Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Bevacizumab Biosimilars Market Competitive Landscape
• 30.2. Bevacizumab Biosimilars Market Company Profiles
  • 30.2.1. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Reliance lifesciences Pvt. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Fujifilm Kyowa Kirin Biologics Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Bevacizumab Biosimilars Market Other Major And Innovative Companies

• 31.1. Teva Pharmaceutical Industries Ltd.
• 31.2. Mylan Inc.
• 31.3. Daiichi Sankyo Company Limited
• 31.4. Beaconpharma Ltd.
• 31.5. Innovent Biologics Inc.
• 31.6. STADA Arzneimittel AG
• 31.7. Shanghai Henlius Biotech Inc.
• 31.8. Aurobindo Pharma Ltd.
• 31.9. Dr. Reddy's Laboratories Ltd.
• 31.10. Biocon Ltd.
• 31.11. Intas Pharmaceuticals Ltd.
• 31.12. Amneal Pharmaceuticals LLC
• 31.13. Samsung Bioepis Co. Ltd.
• 31.14. Celltrion Inc.
• 31.15. Coherus BioSciences Inc.

32. Global Bevacizumab Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bevacizumab Biosimilars Market

34. Recent Developments In The Bevacizumab Biosimilars Market

35. Bevacizumab Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Bevacizumab Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Bevacizumab Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Bevacizumab Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer